Vivos Therapeutics Holds Annual Stockholders Meeting

Vivos Therapeutics ( (VVOS) ) has shared an announcement.

On November 4, 2025, Vivos Therapeutics, Inc. held its annual meeting of stockholders, where key decisions were made regarding the company’s governance and strategic direction. The stockholders elected six directors to the board for a one-year term, approved an amendment to the 2024 Omnibus Equity Incentive Plan, and ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s operational strategies and financial oversight, reinforcing its governance structure and aligning its incentive plans with future growth objectives.

The most recent analyst rating on (VVOS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Vivos Therapeutics stock, see the VVOS Stock Forecast page.

Spark’s Take on VVOS Stock

According to Spark, TipRanks’ AI Analyst, VVOS is a Neutral.

Vivos Therapeutics faces significant financial challenges, with ongoing profitability issues and negative cash flow. Technical indicators show bearish trends, and valuation metrics suggest potential overvaluation. While strategic initiatives and financing offer future growth potential, current financial performance and market sentiment weigh heavily on the stock score.

To see Spark’s full report on VVOS stock, click here.

More about Vivos Therapeutics

Vivos Therapeutics, Inc. operates in the healthcare industry, focusing on therapeutic solutions. The company is known for its innovative products and services aimed at addressing various health conditions, with a particular market focus on medical treatments and healthcare technologies.

Average Trading Volume: 279,020

Technical Sentiment Signal: Sell

Current Market Cap: $18.54M

Learn more about VVOS stock on TipRanks’ Stock Analysis page.